-transparent.png){kind=logo}
Human synoviocytes in culture respond to prostaglandin E1 (PGE1) by increasing their intracellular concentration of cyclic AMP. Readdition of PGE1 to cells previously treated with PGE1 elicits no change in the intracellular concentration of cyclic AMP. This refractory state is partially prevented by the inhibitors of protein synthesis, puromycin (PM) and cycloheximide (CH). Indomethacin (IM), which reduces angiotensin tachyphylaxis, does not prevent the occurrence of refractoriness to PGE1 with respect to accumulation of cyclic AMP. This agent does alter the release of cyclic AMP from human synovial cells. We postulate that other factors, independent of new protein synthesis, are necessary for the development of the complete PGE1 refractory state in these cells.
C P Ciosek, and
J V Fahey, and
Y Ishikawa, and
D S Newcombe
September 1974,
Nature,
C P Ciosek, and
J V Fahey, and
Y Ishikawa, and
D S Newcombe
April 1979,
The American journal of physiology,
C P Ciosek, and
J V Fahey, and
Y Ishikawa, and
D S Newcombe
January 1983,
Medical biology,
C P Ciosek, and
J V Fahey, and
Y Ishikawa, and
D S Newcombe
December 1973,
Proceedings of the National Academy of Sciences of the United States of America,
C P Ciosek, and
J V Fahey, and
Y Ishikawa, and
D S Newcombe
January 1978,
Advances in cyclic nucleotide research,
C P Ciosek, and
J V Fahey, and
Y Ishikawa, and
D S Newcombe
February 1983,
Steroids,
C P Ciosek, and
J V Fahey, and
Y Ishikawa, and
D S Newcombe
September 1989,
Prostaglandins, leukotrienes, and essential fatty acids,
C P Ciosek, and
J V Fahey, and
Y Ishikawa, and
D S Newcombe
January 1980,
Current topics in cellular regulation,
C P Ciosek, and
J V Fahey, and
Y Ishikawa, and
D S Newcombe
May 1975,
The Journal of physiology,
C P Ciosek, and
J V Fahey, and
Y Ishikawa, and
D S Newcombe
September 1973,
Nature: New biology,
